首页> 外国专利> GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES, INTERMEDIATES THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES, INTERMEDIATES THEREOF, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

机译:3-或4-取代的4-(氨基甲基)-哌啶衍生物的胃动力学双环苯甲酰胺,介导其中间体,其制备方法和组成它们的药物组合物

摘要

Compounds of the formula a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid or base addition salt thereof, wherein R1 and R2 taken together form a bivalent radical of the formula -O-CH2-O-, -O-CH2-CH2-, -O-CH2-CH2-O-, -O-CH2-CH-CH2-, -O-CH2-CH2-CH2-O-, -O-CH2-CH2-CH2-CH2- 1418 א' בתמוז התשס" ד - June 20, 2004 wherein in said bivalent radical one or two hydrogen atoms may be substituted with C1-6 alkyl, R3 is hydrogen or halo; R4 is hydrogen or C1-6 alkyl; R5 is hydrogen or C1-6 alkyl; L is hydrogen, C3-6 cycloalkyl, C5-6 cycloalkanone or C2-6 alkenyl, or L is a radical of the formula -Alk-R6, -Alk-X-R7, -Alk-Y-C(=O)-R9 or -Alk-Y-C(=O)-NR11R12 wherein each Alk is C1-12 alkenediyl; and R6 is hydrogen, hydroxy, cyano, C1-6 alkylsulfonylamino, C3-6 cycloalkyl, C5-6 cycloalkanone, or Het1; R7 is hydrogen, C1-6 alkyl, hydroxy C1-6 alkyl, C3-6 cycloalkyl, or Het2; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6 alkyl; R9 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen or C1-6 alkyl; R11 and R12 each independently are hydrogen, C1-6 alkyl, C3-6 cycloalkyl, or R11 and R12 combined with the nitrogen atom bearing R11 and R12 may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C1-6 alkyl, amino or mono or di(C1-6 alkyl) amino, or said R11 and R12 combined with the nitrogen bearing R11 and R12 may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C1-6 alkyl; and Het1 and Het2 each independently are selected from furan; furan subsituted with C1-6 alkyl or halo; tetrahydrofuran; a tetrahydrofuran substituted with C1-6 alkyl; a dioxolane; a dioxolane substituted with C1-6 alkyl, a dioxane; a dioxane substituted with C1-6 alkyl; tetrahydropyran; a tetrahydropyran substituted with C1-6; pyrrolidinyl; pyrrolidinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, or C1-6 alkyl; pyridinyl; pyridinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6 alkyl; pyrimidinyl; pyrimidinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6 alkyl, C1-6 alkyloxy, amino and mono and di(C1-6 alkyl) amino; pyridazinyl; pyridazinyl substituted with one or two substituents each independently selected from hydroxy, C1-6 alkyloxy, C1-6 alkyl or halo; pyrazinyl; pyrazinyl substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6 alkyl, C1-6 alkyloxy, amino, mono- and di(C1-6 alkyl) amino and C1-6 alkyloxycarbonyl; Het1 can also be a radical of the formula Het1 and Het2 each independently can also be selected from the radicals of the formula R13 and R14 each independently are hydrogen or C1-4 alkyl. 1419 א' בתמוז התשס" ד - June 20, 2004
机译:下式的化合物为立体化学异构体形式,其N-氧化物形式或其药学上可接受的酸或碱加成盐,其中R1和R2一起形成式-O-CH2-O-,-O的二价基团-CH2-CH2-,-O-CH2-CH2-O-,-O-CH2-CH-CH2-,-O-CH2-CH2-CH2-O-,-O-CH2-CH2-CH2-CH2- 1418 2004年6月20日,其中在所述二价基团中,一个或两个氢原子可被C1-6烷基取代,R3为氢或卤素; R4为氢或C1-6烷基; R5为氢或C1 -6烷基; L是氢,C3-6环烷基,C5-6环烷酮或C2-6烯基,或者L是式-Alk-R6,-Alk-X-R7,-Alk-YC(= O )-R9或-Alk-YC(= O)-NR11R12,其中每个Alk为C1-12亚烷基; R6为氢,羟基,氰基,C1-6烷基磺酰基氨基,C3-6环烷基,C5-6环烷酮或Het1; R 7是氢,C 1-6烷基,羟基C 1-6烷基,C 3-6环烷基或Het 2; X是O,S,SO 2或NR 8;所述R 8是氢或C 1-6。烷基; R9是氢,C1-6烷基,C3-6环烷基,C1-6烷氧基或羟基; Y为NR10或直接键;所述R 10为氢或C 1-6烷基; R 11和R 12各自独立地是氢,C 1-6烷基,C 3-6环烷基,或者R 11和R 12与带有R 11和R 12的氮原子结合可以形成吡咯烷基或哌啶基环,两者均任选地被C 1-6烷基,氨基或单或二(C 1-6烷基)氨基,或所述R 11和R 12与含氮的R 11和R 12结合可形成均被C 1-6烷基任选取代的哌嗪基或4-吗啉基。和Het1和Het2各自独立地选自呋喃;用C 1-6烷基或卤素取代的呋喃;四氢呋喃被C 1-6烷基取代的四氢呋喃;二氧戊环;被C 1-6烷基取代的二氧戊环,即二恶烷;被C 1-6烷基取代的二恶烷;四氢吡喃;被C 1-6取代的四氢吡喃;吡咯烷基;被一个或两个独立地选自卤素,羟基,氰基或C 1-6烷基的取代基取代的吡咯烷基;吡啶基被一个或两个各自独立地选自卤素,羟基,氰基,C 1-6烷基的取代基取代的吡啶基;嘧啶基被一个或两个独立地选自卤素,羟基,氰基,C 1-6烷基,C 1-6烷氧基,氨基和单和二(C 1-6烷基)氨基的取代基取代的嘧啶基;哒嗪基;被一个或两个独立地选自羟基,C 1-6烷氧基,C 1-6烷基或卤素的取代基取代的哒嗪基;吡嗪基被一个或两个独立地选自卤素,羟基,氰基,C 1-6烷基,C 1-6烷氧基,氨基,单和二(C 1-6烷基)氨基和C 1-6烷氧基羰基的取代基取代的吡嗪基; Het1也可以分别是式Het1和Het2的基团,也可以选自式R13和R14的基团,每个基团分别是氢或C1-4烷基。 1419א'בתמוזהתשס"תשס-2004年6月20日

著录项

  • 公开/公告号IL133918B

    专利类型

  • 公开/公告日2004-06-20

    原文格式PDF

  • 申请/专利权人 JANSSEN PHARMACEUTICA N.V.;

    申请/专利号IL133918

  • 发明设计人

    申请日2000-01-07

  • 分类号

  • 国家 IL

  • 入库时间 2022-08-21 23:10:41

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号